cellular therapy; cornea; eye; horse; immune system disease; immunomodulation; Veterinary (all); General Veterinary
Abstract :
[en] [en] OBJECTIVE: To establish the safety of subconjunctival injections of autologous muscle-derived mesenchymal stem cells (mdMSCs) in healthy horses and to evaluate their effect in four horses (six eyes) with severe chronic equine immune-mediated keratitis (IMMK) that was unresponsive to medical treatments.
METHODS: MdMSCs were cultured from minimally invasive muscle biopsies. In the safety group, four healthy horses received two subconjunctival injections of 2.5 and 5 million cells, respectively, at 1-month interval, to the same eye. Ocular side effects were monitored for 1 month following each injection. In the treatment group, six eyes received four to seven subconjunctival mdMSCs injections (2.5 or 5 million cells per injection) every 4 weeks, approximatively. Medical treatment was discontinued 1 week before and throughout the entire treatment period. A scoring system was used to assess the evolution of the ocular lesions.
RESULTS: In the safety group, all horses exhibited mild to moderate chemosis and conjunctival hyperemia at the injection site, lasting 24-48 h. In the treatment group, all eyes initially responded positively to therapy, with a reduction in lesion scores observed after the first injection. Four eyes achieved control of the lesions with repeated injections during the 9.2 months of follow-up.
CONCLUSION: The first subconjunctival injection of mdMSCs resulted in improvement of the ocular lesions. Repeated injections were found to be safe, minimally invasive and showed promise in managing refractory cases of equine IMMK. Further studies are warranted to demonstrate the long-term benefits of these injections and to optimize the therapeutic protocol.
Narinx, Florine ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Médecine vétérinaire comparée
Sauvage, Aurélie ; Université de Liège - ULiège > Département d'Enseignement et de Clinique des Equidés (DCE) > Ophtalmologie des équidés
Ceusters, Justine ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Médecine vétérinaire comparée
Grulke, Sigrid ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Médecine vétérinaire comparée
Serteyn, Didier ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Médecine vétérinaire comparée
Monclin, Sébastien ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Médecine vétérinaire comparée
Language :
English
Title :
Subconjunctival autologous muscle-derived mesenchymal stem cell therapy: A novel, minimally invasive approach for treating equine immune-mediated keratitis.
Alternative titles :
[fr] Thérapie sous-conjonctivale avec des cellules souches mésenchymateuses autologues d'origine musculaire: Une nouvelle approche minimal-invaisve pour le traitement de la kératite à médiation immunitaire équine.
Brooks DE, Matthews A, Clode AB. Disease of the cornea. In: Gilger BC, ed. Equine Ophthalmology. 3th ed. Wiley-Blackwell; 2017:253-368.
Matthews A, Gilger B. Equine immune-mediated keratopathies. Equine Vet J. 2010;37:31-37.
Pate D, Clode A, Olivry T, Cullen J, Salmon J, Gilger B. Immunohistochemical and immunopathologic characterization of superficial stromal immune-mediated keratitis in horses. Am J Vet Res. 2012;73:1067-1073.
Gilger B, Michau T, Salmon J. Immune-mediated keratitis in horses: 19 cases (1998–2004). Vet Ophthalmol. 2005;8:233-239.
Gilger BC, Stoppini R, Wilkie DA, et al. Treatment of immune-mediated keratitis in horses with episcleral silicone matrix cyclosporine delivery devices. Vet Ophthalmol. 2014;1:23-30.
Dieterman E, Hermans H, Slenter I, Kuijpers N, Grinwis G, Boevé M. Outcome of superficial keratectomy without conjunctival graft as a surgical technique for immune-mediated keratitis in horses: four cases. Equine Vet Edu. 2022;34:323-330.
Ghiasi M, Jadidi K, Hashemi M, Zare H, Salimi A, Aghamollaei H. Application of mesenchymal stem cells in corneal regeneration. Tissue Cell. 2021;73:101600.
Cejka C, Holan V, Trosan P, Zajicova A, Javorkova E, Cejkova J. The favorable effect of mesenchymal stem cell treatment on the antioxidant protective mechanism in the corneal epithelium and renewal of corneal optical properties changed after alkali burns. Oxid Med Cell Longev. 2016;4:1-12.
Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med. 2012;4:1-12.
Carrade Holt DD, Wood JA, Granick JL, Walker NJ, Clark KC, Borjesson DL. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. Stem Cells Dev. 2014;23:1258-1265.
Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20:419-427.
Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;4:653-664.
Zakirova EY, Valeeva AN, Aimaletdinov AM, et al. Potential therapeutic application of mesenchymal stem cells in ophthalmology. Exp Eye Res. 2019;189:107863.
Davis AB, Schnabel LV, Gilger BC. Subconjunctival bone marrow-derived mesenchymal stem cell therapy as a novel treatment alternative for equine immune-mediated keratitis: a case series. Vet Ophthalmol. 2019;22:674-682.
Frisbie DD, Smith RK. Clinical update on the use of mesenchymal stem cells in equine orthopaedics. Equine Vet J. 2010;42:86-89.
Fortier LA, Travis AJ. Stem cells in veterinary medicine. Stem Cell Res Ther. 2011;2:9-15.
Mafi R, Hindocha S, Mafi P, Griffin M, Khan WS. Sources of adult mesenchymal stem cells applicable for musculoskeletal applications – a systematic review of the literature. Open Orthop J. 2011;5:242-248.
Radtke CL, Nino-Fong R, Esparza Gonzalez BP, Stryhn H, McDuffee LA. Characterization and osteogenic potential of equine muscle tissue- and periosteal tissue-derived mesenchymal stem cells in comparison with bone marrow- and adipose tissue-derived mesenchymal stem cells. Am J Vet Res. 2013;74:790-800.
Ceusters J, Lejeune JP, Sandersen C, Niesten A, Lagneaux L, Serteyn D. From skeletal muscle to stem cells: an innovative and minimally-invasive process for multiple species. Sci Rep. 2017;71:696.
Eaton JS, Miller PE, Bentley E, Thomasy SM, Murphy CJ. The SPOTS system: an ocular scoring system optimized for use in modern preclinical drug development and toxicology. J Ocul Pharmacol Ther. 2017;33:718-734.
Zhang L, Coulson-Thomas VJ, Ferreira TG, Kao WW. Mesenchymal stem cells for treating ocular surface diseases. BMC Ophthalmol. 2015;15:155.
Zhou Y, Chen Y, Wang S, Qin F, Wang L. MSCs helped reduce scarring in the cornea after fungal infection when combined with anti-fungal treatment. BMC Ophthalmol. 2019;19:226.
Song HB, Park SY, Ko JH, et al. Mesenchymal stromal cells inhibit inflammatory Lymphangiogenesis in the cornea by suppressing macrophage in a TSG-6-dependent manner. Mol Ther. 2018;26:162-172.
Kossl J, Bohacova P, Hermankova B, Javorkova E, Zajicova A, Holan V. Antiapoptotic properties of mesenchymal stem cells in a mouse model of corneal inflammation. Stem Cells Dev. 2021;30:418-427.
Dechêne L, Colin M, Demazy C, et al. Characterization of the proteins secreted by equine muscle-derived mesenchymal stem cells exposed to cartilage explants in osteoarthritis model. Stem Cell Rev Rep. 2023;19:550-567.
Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro. Stem Cell Res Ther. 2014;5:13.
Pezzanite LM, Fortier LA, Antczak DF, et al. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo. Stem Cell Res Ther. 2015;6:1.
Galindo S, de la Mata A, López-Paniagua M, et al. Subconjunctival injection of mesenchymal stem cells for corneal failure due to limbal stem cell deficiency: state of the art. Stem Cell Res Ther. 2021;12:60.
Sohni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013;2013:130763.
Di G, Du X, Qi X, et al. Mesenchymal stem cells promote diabetic corneal epithelial wound healing through TSG-6-dependent stem cell activation and macrophage switch. Invest Ophthalmol Vis Sci. 2017;58:4344-4354.
Shukla S, Mittal SK, Foulsham W, et al. Therapeutic efficacy of different routes of mesenchymal stem cell administration in corneal injury. Ocul Surf. 2019;17:729-736.
Ghazaryan E, Zhang Y, He Y, et al. Mesenchymal stem cells in corneal neovascularization: comparison of different application routes. Mol Med Rep. 2016;14:3104-3112.
Yao L, Li ZR, Su WR, et al. Role of mesenchymal stem cells on cornea wound healing induced by acute alkali burn. PLoS ONE. 2012;7:e30842.
Zhang N, Luo X, Zhang S, et al. Subconjunctival injection of tumor necrosis factor-α pre-stimulated bone marrow-derived mesenchymal stem cells enhances anti-inflammation and anti-fibrosis in ocular alkali burns. Graefes Arch Clin Exp Ophthalmol. 2021;259:929-940.